Search results for "From ACP Internist Weekly"
ADA updates diabetes standards of care for 2023
The American Diabetes Association (ADA) has changed its recommendations on hypertension cutoffs, use of statins, and treatment of patients with diabetes and chronic kidney disease, among other topics.
https://diabetes.acponline.org/archives/2023/01/13/5.htm
13 Jan 2023
Troponin concentration may help stratify risk in those with stable ischemic heart disease and diabetes
Researchers used a high-sensitivity assay to measure cardiac troponin T concentration at baseline, then analyzed whether it was associated with a composite end point (death from cardiovascular causes, myocardial infarction, or stroke).
https://diabetes.acponline.org/archives/2015/09/11/5.htm
11 Sep 2015
SGLT-2 inhibitors associated with lower risk of gout vs. GLP-1 receptor agonists
In a large, propensity-matched study, adult patients with type 2 diabetes who were newly prescribed a sodium-glucose cotransporter-2 (SGLT-2) inhibitor had a lower rate of incident gout than those newly prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist.
https://diabetes.acponline.org/archives/2020/02/14/7.htm
14 Feb 2020
Racial, economic disparities found in use of SGLT2 inhibitors
Although use of sodium-glucose cotransporter-2 (SGLT2) inhibitors rose overall between 2015 and 2019, patients who were Black, Asian, female, or with lower household income had lower rates of prescriptions for the drug class than others with type 2 diabetes.
https://diabetes.acponline.org/archives/2021/05/14/8.htm
14 May 2021
New recommendations advise on adding SGLT-2 inhibitors and GLP-1 receptor agonists
A new guideline from The BMJ strongly recommends sodium-glucose cotransporter-2 (SGLT-2) inhibitors for patients with diabetes and established cardiovascular and chronic kidney disease, in addition to offering weaker support for starting glucagon-like peptide-1 (GLP-1) receptor agonists in this same patient population.
https://diabetes.acponline.org/archives/2021/06/11/7.htm
11 Jun 2021
GLP-1 receptor agonists associated with thyroid cancer
Patients taking a glucagon-like peptide-1 (GLP-1) receptor agonist had about one and a half times the risk of developing thyroid cancer compared to similar controls, according to an observational French study.
https://diabetes.acponline.org/archives/2022/12/09/6.htm
9 Dec 2022
Weight loss program may improve HbA1c more than typical diabetes nutrition counseling, study finds
Patients participating in Weight Watchers program supplemented with diabetes education lost more weight than a control group by 3, 6, 9, and 12 months of follow-up.
https://diabetes.acponline.org/archives/2016/11/11/8.htm
11 Nov 2016
Some newer diabetes drugs may help decrease risk of COPD exacerbation
A cohort study in the United Kingdom found that chronic obstructive pulmonary disease (COPD) exacerbations were less common in patients with type 2 diabetes and COPD taking glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors versus sulfonylureas.
https://diabetes.acponline.org/archives/2022/11/11/6.htm
11 Nov 2022
SGLT-2 inhibitors not associated with increased risk for severe UTIs
An accompanying editorial said that while the study's finding is reassuring, it should be considered with caution, especially since high-risk patients and those with previous urinary tract infections (UTIs) were excluded.
https://diabetes.acponline.org/archives/2019/08/09/7.htm
9 Aug 2019
USPSTF lowers age for starting diabetes screening from 40 to 35 years
Primary care clinicians should screen all overweight or obese adults ages 35 to 70 years for diabetes and prediabetes and should offer interventions for those with either condition, the U.S. Preventive Services Task Force (USPSTF) recently recommended.
https://diabetes.acponline.org/archives/2021/09/10/6.htm
10 Sep 2021